MEK1 antibody | knockout validation | Cell Signaling 2352
DOI
//dx.doi.org/10.13070/ko.en.7.2003
Date
2017-01-20

This is a knockout-validated antibody summary, based on the publication "MEK1 is required for the development of NRAS-driven leukemia", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

MEK1 antibody | knockout validation | Cell Signaling 2352 figure 1
Figure 1. Immunoblot analysis of clonal cell lines derived from HL-60 cells nucleofected with pSpCas9(BB)-2A-GFP plasmid expressing single guide RNA (sgRNA) against exon1 of MEK1 gene. Non nucleofected, wild type HL-60 cell line (WT) serves as a MEK1-positive control; TUBA serves as a loading control. Courtesy of the Authors [1].
Antibody information

Mouse monoclonal IgG2a

Company: Cell Signaling

Antibody: MEK1

Catalog number: 2352

Summary: Mouse monoclonal IgG2a against full length MEK1 protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot and immunoprecipitation.

Validation Method

Western blot

Sample

Wild type and MEK1-KO human HL-60 leukemia cell line. Cells were lysed in buffer containing 20 mM TrisHCl pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1% NP-40, 1 mM Na3VO4, 50 mM NaF, 2 mM PMSF and protease inhibitor cocktail (Roche).

Blocking agent

5% milk in TBS-T for 1hr.

Primary incubation

for 1hr at room temperature or overnight at 4°C.

Detection

SuperSignal West Pico/Femto Chemiluminescent Substrate (Thermo Scientific), Amersham Hyperfilm (Ge Healthcare) and CURIX 60 processor (Agfa) or ChemiDoc Touch Imaging System (Bio-Rad).

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Nowacka J, Baumgartner C, Pelorosso C, Roth M, Zuber J, Baccarini M. MEK1 is required for the development of NRAS-driven leukemia. Oncotarget. 2016;: pubmed publisher